YTHu78
YTHu78 is a KDM5B PROTAC degrader. YTHu78 induces KDM5B degradation via the ubiquitin-proteasome system and CRBN E3 ligase, and triggers lytic apoptosis in hematologic malignant cells. YTHu78 can be used in studies related to hematologic malignancies.
(Pink: KDM5 ligand (HY-116761); Blue: Cereblon ligand (HY-14658); Black: linker).
For research use only. We do not sell to patients.
- Formula: C33H28N8O6
- Molecular Weight:632.63
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
KDM5B |
Caspase 3 |
Cereblon |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MV4-11 | IC50 |
1.34 μM
|
Antiproliferative activity against human myeloid monocytic leukemia MV-4-11 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human myeloid monocytic leukemia MV-4-11 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| HL-60 | IC50 |
6.583 μM
|
Antiproliferative activity against human hematologic malignancy HL-60 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human hematologic malignancy HL-60 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| MM.1S | IC50 |
1.036 μM
|
Antiproliferative activity against human hematologic malignancy MM.1S cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human hematologic malignancy MM.1S cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| MV4-11 | IC50 |
1.489 μM
|
Antiproliferative activity against human hematologic malignancy MV-4-11 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human hematologic malignancy MV-4-11 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| OCI-AML-3 | IC50 |
9.074 μM
|
Antiproliferative activity against human hematologic malignancy OCI-AML3 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human hematologic malignancy OCI-AML3 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| HUVEC | IC50 |
>20 μM
|
Antiproliferative activity against normal human HUVEC cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against normal human HUVEC cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| HaCaT | IC50 |
>20 μM
|
Antiproliferative activity against normal human HaCaT cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against normal human HaCaT cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| GES1 | IC50 |
>20 μM
|
Antiproliferative activity against normal human GES-1 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against normal human GES-1 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| HEK293 | IC50 |
>20 μM
|
Antiproliferative activity against normal human HEK293 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against normal human HEK293 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| Huh-7 | IC50 |
6.04 μM
|
Antiproliferative activity against human solid tumor Huh-7 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor Huh-7 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| PANC-1 | IC50 |
17.67 μM
|
Antiproliferative activity against human solid tumor PANC-1 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor PANC-1 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| HCC1937 | IC50 |
15.41 μM
|
Antiproliferative activity against human solid tumor HCC1937 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor HCC1937 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| SNU-387 | IC50 |
>20 μM
|
Antiproliferative activity against human solid tumor SNU-387 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor SNU-387 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| A 172 | IC50 |
>20 μM
|
Antiproliferative activity against human solid tumor A-172 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor A-172 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| U-87MG ATCC | IC50 |
>20 μM
|
Antiproliferative activity against human solid tumor U87MG cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor U87MG cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
| MDA-MB-468 | IC50 |
>20 μM
|
Antiproliferative activity against human solid tumor MDA-MB-468 cells assessed by CCK-8 assay after 72 h incubation.
Antiproliferative activity against human solid tumor MDA-MB-468 cells assessed by CCK-8 assay after 72 h incubation.
|
40578256 |
In Vitro
YTHu78 (0.03 µM-20 µM; 24-48 h) significantly inhibits cell viability, markedly increases the proportion of cells at the late apoptotic stage, induces mild G0/G1 cell cycle arrest, activates Caspase-3, triggers the cleavage of PARP, GSDMD and GSDME, and induces significant lactate dehydrogenase (LDH) release in MV-4-11 (IC50 = 1.34 µM) and MM.1S (IC50 = 1.036 µM) cells[1].
YTHu78 (0.03 µM-20 µM; 1-24 h) effectively induces time-dependent degradation of KDM5B protein without significantly affecting its mRNA level in MV-4-11 and MM.1S cells, exerts no obvious effect on KDM5A, and additionally increases the expression level of H3K4me3[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MV-4-11, HL60, MM.1S, and OCI-AML3 cell lines
-
Concentration:0.03, 0.08, 0.25, 0.74, 2.2, 6.7, 20 µM
-
Incubation Time:72 h
-
Result:Significantly inhibited the proliferation of hematologic malignancy cells.
-
Cell Line:MV-4-11 and MM.1S cell lines
-
Concentration:0.03, 0.08, 0.25, 0.74, 2.2, 6.7, 20 µM (and 5 µM alone)
-
Incubation Time:1, 3, 6, 12, 24, 48 h
-
Result:Effectively induced KDM5B protein degradation, increased H3K4me3 levels, and activated apoptosis and pyroptosis-related executors (such as Caspase-3, GSDMD, and GSDME cleavage).
-
Cell Line:MV-4-11 and MM.1S cell lines
-
Concentration:0.03, 0.08, 0.25, 0.74, 2.2, 6.7, 20 µM
-
Incubation Time:48 h
-
Result:Significantly increased the proportion of late-stage apoptotic cells and compromised cell membrane integrity.
-
Cell Line:MV-4-11 and MM.1S cell lines
-
Concentration:0.03, 0.08, 0.25, 0.74, 2.2, 6.7, 20 µM
-
Incubation Time:24 h
-
Result:Induced a mild G0/G1 phase cell cycle arrest.
Chemical Information
-
Molecular Weight 632.63
-
Formula C33H28N8O6
-
SMILES
O=C1NC(OC2=CN(CC3=CC=C(CCCNC4=CC=CC(C(N5C6CCC(NC6=O)=O)=O)=C4C5=O)C=C3)N=C2)=NC7=CN=CC=C71
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)